GlassScriptPhysician profile
Grant E Hawkins
NPI 1255341806
$542.28
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.39 · 2024: $95.61 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.46 | 2025 | Evenity, Repatha, Otezla |
| Inspire Medical Systems, INC. | $64.54 | 2025 | Inspire |
| Lilly USA, LLC | $47.84 | 2025 | Mounjaro, Jardiance, Zepbound |
| Paratek Pharmaceuticals, INC. | $36.90 | 2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals LP | $34.96 | 2025 | Airsupra |
| Abbvie INC. | $33.48 | 2024-2025 | |
| Glaxosmithkline, LLC. | $31.87 | 2024 | Shingrix, Arexvy |
| Viiv Healthcare Company | $31.54 | 2025 | Dovato |
| Actelion Pharmaceuticals US, INC. | $28.07 | 2025 | Opsumit |
| Boston Scientific Corporation | $25.14 | 2023 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.86 | 2025 | |
| Merck Sharp & Dohme LLC | $17.45 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Dexcom, INC. | $15.87 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $15.25 | 2023 | Livalo |
| Janssen Pharmaceuticals, INC | $15.21 | 2024 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.20 | 2025 | Wegovy |
| Medtronic, INC. | $14.42 | 2025 | Minimed 780g |
| Idorsia Pharmaceuticals US INC | $14.22 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Hawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.